Twist Bioscience Co. (NASDAQ:TWST) SVP Sells $12,128.88 in Stock

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) SVP Paula Green sold 291 shares of the firm's stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $41.68, for a total value of $12,128.88. Following the transaction, the senior vice president now directly owns 130,621 shares in the company, valued at $5,444,283.28. This trade represents a 0.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Paula Green also recently made the following trade(s):

• On Thursday, March 6th, Paula Green sold 918 shares of Twist Bioscience stock. The shares were sold at an average price of $40.91, for a total transaction of $37,555.38.
• On Monday, February 3rd, Paula Green sold 1,259 shares of Twist Bioscience stock. The stock was sold at an average price of $49.35, for a total transaction of $62,131.65.
• On Friday, January 3rd, Paula Green sold 160 shares of Twist Bioscience stock. The shares were sold at an average price of $45.59, for a total transaction of $7,294.40.

Twist Bioscience Trading Down 3.1 %

TWST traded down $1.28 during trading on Friday, reaching $40.30. The company had a trading volume of 423,185 shares, compared to its average volume of 941,430. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96. Twist Bioscience Co. has a 12-month low of $27.41 and a 12-month high of $60.90. The company has a market cap of $2.40 billion, a price-to-earnings ratio of -11.92 and a beta of 2.15. The firm's 50-day simple moving average is $45.30 and its 200 day simple moving average is $45.31.

Remove Ads

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.09. The business had revenue of $88.70 million for the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The firm's quarterly revenue was up 24.1% compared to the same quarter last year. During the same period last year, the firm posted ($0.75) earnings per share. Equities research analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Robert W. Baird upped their target price on Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a research report on Tuesday, February 4th. JPMorgan Chase & Co. upped their price objective on Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a report on Tuesday, February 4th. Barclays set a $58.00 target price on Twist Bioscience and gave the stock an "overweight" rating in a report on Monday, February 3rd. Scotiabank reiterated an "outperform" rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. Finally, Wolfe Research initiated coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They set an "outperform" rating and a $60.00 price objective for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, Twist Bioscience has a consensus rating of "Moderate Buy" and an average target price of $54.40.

Institutional Trading of Twist Bioscience

Several large investors have recently added to or reduced their stakes in TWST. Intech Investment Management LLC purchased a new position in shares of Twist Bioscience during the third quarter valued at $714,000. Massachusetts Financial Services Co. MA grew its stake in Twist Bioscience by 215.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company's stock valued at $1,324,000 after acquiring an additional 20,035 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Twist Bioscience by 4.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 524,942 shares of the company's stock valued at $23,717,000 after acquiring an additional 24,582 shares in the last quarter. Algert Global LLC increased its holdings in shares of Twist Bioscience by 59.7% in the 3rd quarter. Algert Global LLC now owns 43,592 shares of the company's stock valued at $1,969,000 after purchasing an additional 16,292 shares during the period. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in shares of Twist Bioscience in the third quarter worth approximately $599,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.